Ph. Jarreau et al., AEROSOLIZED TACHYKININ ANTAGONISTS INHIBIT PENTAMIDINE-INDUCED BRONCHOCONSTRICTION IN GUINEA-PIGS, Fundamental and clinical pharmacology, 10(6), 1996, pp. 518-523
To investigate the role of tachykinins in pentamidine-induced bronchoc
onstriction and airway microvascular leakage in the guinea pig, we exa
mined the effects on bronchoconstriction and microvascular leakage of
the nonpeptide antagonists of NK1 and NK2 tachykinin-receptors, respec
tively, CP-96,345 and SR 48968. Respiratory system resistance was meas
ured by the occlusion method in anaesthetized, tracheotomized and mech
anically ventilated guinea pigs. Airway microvascular permeability was
evaluated by measuring the quantity of Evans blue dye in the trachea
and main bronchi. Aerosolized CP-96,345 or SR 48968 partially abolishe
d pentamidine-induced bronchoconstriction (at 5 to 30 mg/mL pentamidin
e; 60 breaths) whereas the combination of the two prevented it. fn con
trast, CP-96,345 and SR 48968 did not prevent the increase in airway m
icrovascular permeability induced by pentamidine (50 mg/mL; 90 breaths
) whether they were administered separately or together, by aerosol or
intravenously. These results demonstrate that in the guinea pig, pent
amidine-induced bronchoconstriction is mediated through both NK1 and N
K2 tachykinin-receptor activation and that when directly administered
into the airways, tachykinin antagonists effectively prevent pentamidi
ne-induced bronchoconstriction.